Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has been submitted in China for its pipeline antibody drug conjugate (ADC), BRY812. The National Medical Products Administration (NMPA) has accepted the filing, marking a step forward in the potential approval of the LIV-1-targeted ADC for the treatment of general diseases.
LIV-1 as a Therapeutic Target
LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein that possesses zinc transporter and metalloproteinase activity. It plays a significant role in the homeostatic metabolism of zinc within cells and promotes cell growth, making it a critical factor in tumor metastasis and the epithelial-mesenchymal transformation (EMT) process.
BioRay’s BRY812 in Clinical Trials
BioRay highlights that its molecule is the second LIV-1 ADC globally to enter clinical trials, following Seagen’s ladiratuzumab vedotin, which is soon to be acquired by Pfizer. The company believes its molecule may offer advantages over existing competitors, with higher stability in circulation by preventing payload exchange and more selective delivery of toxins to tumor tissue. This results in a superior safety profile, as demonstrated in pre-clinical toxicology studies.-Fineline Info & Tech
